Overview

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib